Table 1.
Study population
| Aspirin (n=427) | Aspirin placebo (n=434) | Total (n=861) | ||
|---|---|---|---|---|
| Time in CAPP2 intervention study (months) | 25·0 (12·5; 0·8–60·6) | 25·4 (14·2; 1·1–74·4) | 25·2 (13·4; 0·8–74·4) | |
| Time since study entry (months) | 56·6 (30·9; 0·8–125·4) | 54·8 (31·8; 1·6–128·0) | 55·7 (31·4; 0·8–128·0) | |
| Participants with first colorectal cancer | ||||
| Since randomisation | 18 | 30 | 48 | |
| Within 2 years of randomisation | 10 | 10 | 20 | |
| More than 2 years from randomisation | 8 | 20 | 28 | |
| Participants with other Lynch syndrome cancers* | ||||
| Since randomisation | 16 | 24 | 40 | |
| Within 2 years of randomisation | 5 | 9 | 14 | |
| More than 2 years from randomisation | 11 | 15 | 26 | |
| Participants with one or more Lynch syndrome cancer (including colorectal) | ||||
| Since randomisation | 34 | 52 | 86 | |
| Within 2 years of randomisation | 15 | 19 | 34 | |
| More than 2 years from randomisation | 19 | 33 | 52 | |
| Participants with non-Lynch syndrome cancers | 19 | 19 | 38 | |
Data are mean (SD; range) or n.
*
Two participants in the placebo group each had a colorectal cancer and another Lynch syndrome cancer; these participants were counted in the rows relating to both colorectal and other Lynch syndrome cancers; in the row relating to all Lynch syndrome cancers, these participants were counted only once.